BAIT
FLT3
CD135, FLK-2, FLK2, STK1, RP11-153M24.3
fms-related tyrosine kinase 3
GO Process (21)
GO Function (5)
GO Component (1)
Gene Ontology Biological Process
- B cell differentiation [ISS]
- cellular response to cytokine stimulus [ISS, TAS]
- common myeloid progenitor cell proliferation [ISS]
- cytokine-mediated signaling pathway [ISS]
- dendritic cell differentiation [ISS]
- hemopoiesis [IDA]
- leukocyte homeostasis [ISS]
- lymphocyte proliferation [ISS]
- myeloid progenitor cell differentiation [ISS]
- peptidyl-tyrosine phosphorylation [TAS]
- positive regulation of MAP kinase activity [TAS]
- positive regulation of MAPK cascade [TAS]
- positive regulation of cell proliferation [TAS]
- positive regulation of phosphatidylinositol 3-kinase activity [TAS]
- positive regulation of phosphatidylinositol 3-kinase signaling [TAS]
- positive regulation of tyrosine phosphorylation of STAT protein [TAS]
- pro-B cell differentiation [ISS]
- protein autophosphorylation [TAS]
- regulation of apoptotic process [TAS]
- transmembrane receptor protein tyrosine kinase signaling pathway [TAS]
- vascular endothelial growth factor signaling pathway [TAS]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
PREY
IFT57
ESRRBL1, HIPPI, MHS4R2
intraflagellar transport 57
GO Process (5)
GO Function (1)
GO Component (5)
Gene Ontology Biological Process
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
Positive Genetic
Mutations/deletions in separate genes, each of which alone causes a minimal phenotype, but when combined in the same cell results in a less severe fitness defect than expected under a given condition. This term is reserved for high or low throughput studies with scores.
Publication
A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220.
Acute myeloid leukemia (AML) is a malignant hematopoietic disease and the most common type of acute leukemia in adults. The mechanisms underlying drug resistance in AML are poorly understood. Activating mutations in FMS-like tyrosine kinase 3 (FLT3) are the most common molecular abnormality in AML. Quizartinib (AC220) is a potent and selective second-generation inhibitor of FLT3. It is in clinical ... [more]
Cancer Res. Dec. 15, 2016; 77(16);4402-4413 [Pubmed: 28625976]
Throughput
- Low Throughput
Ontology Terms
- phenotype: growth abnormality (HP:0001507)
- phenotype: viability (PATO:0000169)
Additional Notes
- CRISPR GI screen
- Cell Line: MV4-11 cells
- Experimental Setup:Drug Exposure, 3 nM AC220
- GIST: A-phenotypic positive genetic interaction
- Library: GECKO
- Significance Threshold: Only screen hits were published
Curated By
- BioGRID